Dexcom (DXCM) Cash from Financing Activities (2010 - 2026)

Dexcom (DXCM) has reported Cash from Financing Activities for 17 consecutive years, with -$607.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 35623.53% year-over-year to -$607.3 million; the TTM figure through Jun 2026 stood at -$2.3 billion (down 220.29% YoY), while the FY2025 annual figure was -$1.7 billion, down 129.5% from the prior year.
• Cash from Financing Activities slipped to -$607.3 million in Q2 2026 per DXCM's latest filing, from -$25.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $939.5 million in Q2 2023 and bottomed at -$1.5 billion in Q4 2025.
• Historically, Cash from Financing Activities has averaged -$218.0 million across 5 years, with a median of -$3.0 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 21948.84% — and 2025, when it slumped 95037.5%.
• Dexcom's Cash from Financing Activities stood at -$1.0 million in 2022, then plunged by 63090.0% to -$631.9 million in 2023, then jumped by 99.75% to -$1.6 million in 2024, then plunged by 95037.5% to -$1.5 billion in 2025, then jumped by 60.1% to -$607.3 million in 2026.
• Business Quant data shows DXCM's Cash from Financing Activities at -$607.3 million in Q2 2026, -$25.0 million in Q1 2026, and -$1.5 billion in Q4 2025.